Inhibition of P-glycoprotein in Caco-2 cells: Effects of herbal remedies frequently used by cancer patients

Xenobiotica

Volumn 38, Issue 6, 2008, Pages 559-573

  Engdal, S ^a,b   Nilsen, O G ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Agaricus; Caco 2 cell transport; Digoxin; Digoxin cellular transport; Efflux transporter; Garlic; Green tea; Herb drug interactions; In vitro; Mistletoe; Natto K2; Noni juice; P glycoprotein inhibitors

Indexed keywords

AGARICUS EXTRACT; DIGOXIN; GARLIC EXTRACT; GLYCOPROTEIN P; GREEN TEA EXTRACT; HERBACEOUS AGENT; MANNITOL; MORINDA CITRIFOLIA EXTRACT; NATTO K2; VERAPAMIL; VISCUM ALBUM EXTRACT;

AGARICUS; ARTICLE; CANCER PATIENT; CELL FUNCTION; CELL STRAIN CACO 2; CONTROLLED STUDY; CYTOTOXICITY; ELECTRIC RESISTANCE; GARLIC; HERBAL MEDICINE; HUMAN; HUMAN CELL; IC 50; NONI JUICE; PERMEABILITY; TEA; VISCUM ALBUM;

AGARICUS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; DIGOXIN; GARLIC; HUMANS; MISTLETOE; MORINDA; P-GLYCOPROTEIN; PLANT PREPARATIONS; SOY FOODS; TEA; VERAPAMIL;

AGARICUS; ALLIUM SATIVUM;

EID: 45849091909     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250801986969     Document Type: Article

References (42)

1. Adachi Y, Suzuki H, Sugiyama Y. 2001. Comparative studies on in vitro methods for evaluating in vivo function of MDR1P-glycoprotein. Pharmaceutical Research 18:1660-1668.
2. Arunkumar A, Vijayababu MR, Srinivasan N, Aruldhas MM, Arunakaran J. 2006. Garlic compound, diallyl disulfide induces cell cycle arrest in prostate cancer cell line PC-3. Molecular Cell Biochemistry 288:107-113.
3. Balayssac D, Authier N, Cayre A, Coudore F. 2005, Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicology Letters 156:319-329.
4. Bansal T, Singh M, Mishra G, Talegaonkar S, Khar RK, Jaggi M, Mukherjee R. 2007. Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: Utility in Caco-2 intestinal absorption studies. Journal of Chromatography B Analytical Technology, Biomedicine and Life Sciences 859:261-266.
5. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I. 2003. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br Journal of Clinical Pharmacology 55:203-211.
6. Beijnen JH, Schellens JH. 2004. Drug interactions in oncology. Lancet Oncology 5:489-496.
7. Beulz-Riche D, Robert J, Riche C, Ratanasavanh D. 2002. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemotherapy and Pharmacology 49:274-280.
8. Boon HS, Olatunde F, Zick SM. 2007. Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005. BMC Women's Health 7:4 doi:10.1186/1472-6874-7-4.
9. Braun A, Hammerle S, Suda K, Rothen-Rutishauser B, Gunthert M, Kramer SD, Wunderli-Allenspach H. 2000. Cell cultures as tools in biopharmacy. European Journal of Pharmaceutical Science 11(Suppl. 2):S51-S60.
10. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G. 2005. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: Relevance to in vivo prediction. European Journal of Pharmaceutical Science 26:386-393.
11. Dahlin KL, Bohlin K, Strindlund J, Ryrfeldt A, Cotgreave IA. 1999. Amitriptyline-induced loss of tight junction integrity in a human endothelial - smooth muscle cell bi-layer model. Toxicology 136:1-13.
12. Eizenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van RM, Kessler RC. 1998. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. Journal of the American Medical Association 280:1569-1575.
13. Engdal S, Steinsbekk A, Klepp O, Nilsen OG. 2007. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer, DOI: 10.1007/s00520-007-0371-3.
14. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S. 2001. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. Journal of Pharmacy and Pharmacology 4:176-184.
15. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. 2003. The interaction between St John's wort and an oral contraceptive. Clinical Pharmacology and Therapeutics 74:525-535.
16. Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL. 2006. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. European Journal of Pharmaceutical Science 29:70-81.
17. Hellum BH. 2007. In vitro interactions between medicinal drugs and herbs on cytochrome P-450 metabolism and P-glycoprotein transport. Dissertation, Norwegian University of Science and Technology, Trondheim.
18. Hellum BH, Hu Z, Nilsen OG. 2007. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clinical Pharmacology and Therapeutics 100:23-30.
19. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. 2005. Herb-drug interactions: A literature review. Drugs 65:1239-1282.
20. Ikeda Y, Iki M, Morita A, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. 2006. Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese population-based osteoporosis (JPOS) study. Journal of Nutrition 136:1323-1328.
21. Ioannides C. 2002. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451-478.
22. Jakubikova J, Sedlak J. 2006. Garlic-derived organosulfides induce cytotoxicity, apoptosis, cell cycle arrest and oxidative stress in human colon carcinoma cell lines. Neoplasma 53:191-199.
23. Keogh JP, Kunta JR. 2006. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. European Journal of Pharmaceutical Sciences 27:543-554.
24. Kitagawa S. 2004. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. Journal of Pharmacy and Pharmacology 56:1001-1005.
25. Lawson LD, Gardner CD. 2005. Composition, stability, and bioavailability of garlic products used in a clinical trial. Journal of Agricultural and Food Chemistry 3:6254-6261.
26. Leveque D, Jehl F. 2007. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. Journal of Clinical Pharmacology 47:579-588.
27. Li X, Choi JS. 2007. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. International Journal of Pharmaceutics 337:188-193.
28. Lim SL, Lim LY. 2006. Effects of citrus fruit juices on cytotoxicity and drug transport pathways of Caco-2 cell monolayers. International Journal of Pharmaceutics 307:42-50.
29. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, et al. 2005. Use of complementary and alternative medicine in cancer patients: A European survey. Annals of Oncology 16:655-663.
30. Moschella C, Jaber BL. 2001. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. American Journal of Kidney Diseases 38:1105-1107.
31. Nabekura T, Kamiyama S, Kitagawa S. 2005. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochemical and Biophysical Research Communications 327:866-870.
32. Netsch MI, Gutmann H, Luescher S, Brill S, Schmidlin CB, Kreuter MH, Drewe J. 2005. Inhibitory activity of a green tea extract and some of its constituents on multidrug resistance-associated protein 2 functionality. Planta Medica 71:135-141.
33. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. 2001. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Archives in Pharmacology 364:551-557.
34. Perva-Uzunalic A, Skerget M, Knez Z, Weinreich B, Otto F, Gruner S. 2006. Extraction of active ingredients from green tea (Camellia sinensis): Extraction efficiency of major catechins and caffeine. Food Chemistry 96:597-605.
35. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. 2000. Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics 68:231-237.
36. Shapiro LE, Shear NH. 2002. Drug interactions: Proteins, pumps, and P-450s. Journal of American Academy of Dermatology 47:467-484.
37. Sparreboom A, Cox MC, Acharya MR, Figg WD. 2004. Herbal remedies in the United States: Potential adverse interactions with anticancer agents. Journal of Clinical Oncology 22:2489-2503.
38. Tascilar M, De Jong FA, Verweij J, Mathijssen RHJ. 2006. Complementary and alternative medicine during cancer treatment: Beyond innocence. Oncologist 11:732-741.
39. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences, USA, 84:7735-7738.
40. Verschraagen M, Koks CHW, Schellens JHM, Beijnen JH. 1999. P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacological Research 40:301-306.
41. Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. 2004. Potential health risks of complementary alternative medicines in cancer patients. British Journal of Cancer 90:408-413.
42. Zhu M, Chen Y, Li RC. 2000. Oral absorption and bioavailability of tea catechins. Planta Medica 66:444-447.